14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
EVGN vs KMDA
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
EVGN vs KMDA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KMDA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)
KMDA Overall Winner
6-Pillar Tally: EVGN 0 – 5 KMDA (1 Tie)
Matrix Metrics: EVGN 0 – 10 KMDA
As of Nov 17, 2026, Kamada Ltd (KMDA) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas KMDA carries 42.7/100 (HOLD) at $8.16 (14.1x Forward P/E, 15.4% operating margin).
EVGN
NASDAQ
Evogene Ltd.
Agricultural Chemicals
Market Cap
$6.0M
TTM Revenue
$1.7M
Forward P/E
N/M
Beta / 30D Vol
1.37β · 138% Vol
Unified Composite Score
41.2 / 100
SELL
Tech 25.0
Fund 48.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $0.36 · SMA50: $0.40
KMDA
NASDAQ
Head-to-Head Winner
Kamada Ltd
Pharmaceutical Preparations
Market Cap
$468.2M
TTM Revenue
$197M
Forward P/E
14.1x
Beta / 30D Vol
0.96β · 50% Vol
Unified Composite Score
42.7 / 100
HOLD
Tech 28.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.8 · SMA20: $7.77 · SMA50: $8.04
6-Pillar Scorecard Institutional Category Breakdown (EVGN 0 – 5 KMDA)
Columns: Metric · EVGN · KMDA
1. Valuation Multiples
KMDA
Forward P/E
N/M
14.1x
Trailing P/E
N/M
21.3x
PEG Ratio
N/M
0.64x
EV / Revenue
N/M
2.4x
2. Growth & Scale
KMDA
Revenue Growth (YoY)
-60.7%
+10.7%
Earnings Growth (YoY)
+0.0%
+55.6%
TTM Revenue (USD)
$1.7M
$197M
Market Cap
$6.0M
$468.2M
3. Profitability & Quality
KMDA
Gross Margin
-67.6%
41.6%
Operating Margin
-858.2%
15.4%
Net Profit Margin
0.0%
12.7%
Return on Equity (ROE)
-182.8%
9.3%
4. Balance Sheet & Cash Flow
KMDA
Cash Generation (TTM)
-$11M
$44M EBITDA
Cash Flow Margin
N/A
22.5% EBITDA Mgn
Net Cash / Leverage
$6.5M Net Cash
$4.70 Book/Sh · 9.3% ROE
Dividend Yield
None (0.00%)
2.10%
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
339.1% (50th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
KMDA
OpEx & R&D Intensity
N/A
26.2% of Rev ($52M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EVGN (0) vs KMDA (10)
Institutional Metric
EVGN
KMDA
Criterion
Row Edge
Market Capitalization
Scale
$6.0M
$468.2M
Larger Scale
KMDA
Trailing P/E Ratio
Valuation
N/M
21.3x
Lower Multiple
KMDA
Forward P/E Ratio
Valuation
N/M
14.1x
Lower Multiple
KMDA
Revenue Growth (YoY)
Growth
-60.7%
+10.7%
Higher Growth
KMDA
Operating Margin (TTM)
Profitability
-858.2%
15.4%
Higher Margin
KMDA
Net Profit Margin
Profitability
0.0%
12.7%
Higher Margin
KMDA
Return on Equity (ROE)
Capital Efficiency
-182.8%
9.3%
Higher ROE
KMDA
52-Week Range Position
Momentum
9% ($0–$1)
57% ($7–$9)
Stronger Trend
KMDA
Beta / 30D Volatility
Risk Regime
1.37β · 138% Vol
0.96β · 50% Vol
Lower Realized Risk
KMDA
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL)
42.7 / 100 (HOLD)
Higher Composite
KMDA
Trailing 12M Revenue (USD)
Operating Scale
$1.7M
$197M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-67.6%
41.6%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev
0.64x PEG · 2.4x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($6.5M Net Cash)
$44M EBITDA ($4.70 Book/Sh · 9.3% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
KMDA +14.81 pp
EVGN:
-7.58%
·
KMDA:
+7.23%
3M Horizon
KMDA +46.82 pp
EVGN:
-43.4%
·
KMDA:
+3.42%
6M Horizon
KMDA +61.66 pp
EVGN:
-54.29%
·
KMDA:
+7.37%
1Y Horizon
KMDA +88.63 pp
EVGN:
-71.89%
·
KMDA:
+16.74%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs KMDA. Trailing 12-month operating profitability (EVGN -858.2% vs KMDA 15.4%) and valuation multiples (EVGN N/M vs KMDA 14.1x Forward P/E) are benchmarked directly in Pillar 4 below.
EVGN ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $1.7M
Gross Margin -67.6%
Op. Margin -858.2%
ROE / Fwd P/E -182.8% · N/M
KMDA ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $197M
Gross Margin 41.6%
Op. Margin 15.4%
ROE / Fwd P/E 9.3% · 14.1x
EVGN
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
KMDA
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
339.1%
IV Percentile
50th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
EVGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.0M market capitalization and -858.2% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
KMDA Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $468.2M market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment
26.2% of Rev ($52M)
90D Engineering Disclosures
0 Published
Investor FAQ EVGN vs KMDA Key Questions & Quantitative Answers
Is EVGN or KMDA a better stock to buy right now?
As of Nov 17, 2026, Kamada Ltd (KMDA) is the stronger overall head-to-head candidate over Evogene Ltd. (EVGN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EVGN carries a Unified Composite Score of 41.2/100 (SELL) at $0.34 (N/M Forward P/E, -858.2% operating margin), whereas KMDA carries 42.7/100 (HOLD) at $8.16 (14.1x Forward P/E, 15.4% operating margin). Technically, EVGN sits in a Neutral phase (RSI 47.4, UNCLASSIFIED options structure) and KMDA sits in a Neutral phase (RSI 56.8, UNCLASSIFIED options structure).
Does EVGN or KMDA have stronger revenue and earnings growth?
KMDA leads the Growth & Scale pillar: EVGN posts -60.7% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (-67.6% gross margin, -858.2% operating margin), compared with KMDA at +10.7% YoY revenue growth and +55.6% YoY earnings growth on $197M TTM revenue (41.6% gross margin, 15.4% operating margin). On trailing 12-month operating scale, EVGN generates $1.7M in USD-normalized revenue versus $197M for KMDA. In operating R&D and SG&A reinvestment, EVGN deploys N/A (0 90-day corporate R&D disclosures) versus 26.2% of Rev ($52M) (0 disclosures) for KMDA.
Is EVGN or KMDA cheaper on valuation?
KMDA screens cheaper on headline valuation multiples. EVGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KMDA trades at 14.1x Forward P/E, 21.3x Trailing P/E, 0.64x PEG, and 2.4x EV/Revenue (22.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVGN (-182.8% ROE) versus KMDA (9.3% ROE) capital efficiency.
How is options market volatility positioned on EVGN vs KMDA?
In options market volatility and institutional positioning, EVGN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 138% Vol realized risk). By comparison, KMDA carries 339.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 50% Vol realized risk).
Evogene Ltd. (EVGN) Research Suite
Kamada Ltd (KMDA) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.